Zura Bio Stock (NASDAQ:ZURA)

Forecast Ownership Financials Chart

Previous Close

$6.13

52W Range

$1.88 - $7.44

50D Avg

$5.59

200D Avg

$5.26

Market Cap

$542.44M

Avg Vol (3M)

$1.31M

Beta

-0.04

Div Yield

ZURA Company Profile

Zura Bio Limited is a clinical-stage biotechnology company headquartered in San Diego, California, dedicated to pioneering new therapeutic solutions for immune system and inflammatory diseases. Its key product candidates include ZB-168, an anti-IL7Rα inhibitor engineered to address conditions influenced by the IL7 and TSLP biological pathways. The company is also advancing Torudokimab, a monoclonal antibody that neutralizes IL-33, which is currently in Phase 2 clinical development.

Industry

Biotechnology

Sector

Healthcare

Exchange

NASDAQ

ADR

Country

Employees

IPO Date

Mar 21, 2023

Website

ZURA Performance

ZURA Financial Summary

	Dec 25	Dec 24	Dec 23
Revenue	-	-	-
Operating Income	$-75.25M	$-55.19M	$-62.64M
Net Income	$-99.35M	$-52.40M	$-60.36M
EBITDA	$-75.25M	$-55.18M	$-62.64M
Basic EPS	$-1.06	$-0.60	$-2.09
Diluted EPS	$-1.06	$-0.60	$-2.09

Fiscal year ends in Dec 25 | Currency in USD

Peer Comparison

Ticker	Company
TNYA	Tenaya Therapeutics, Inc.
AARD	Aardvark Therapeutics, Inc. Common Stock
ENTA	Enanta Pharmaceuticals, Inc.
FHTX	Foghorn Therapeutics Inc.
IMRX	Immuneering Corporation
SGMT	Sagimet Biosciences Inc.
PYXS	Pyxis Oncology, Inc.
ARCT	Arcturus Therapeutics Holdings Inc.
ASMB	Assembly Biosciences, Inc.
NAUT	Nautilus Biotechnolgy, Inc.